Oculis Holding AG Ordinary shares
OCS
Closed
$13.70
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The company is headquartered in Zug, Zug and currently employs 60 full-time employees. The company went IPO on 2023-03-03. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Key stats
Open
$13.51
Volume
524.78K
Market cap
$969.69M
Prev. close
$13.70
Impl / hst vl
-
Open interest
$0.00
$13.23
Day’s Range
$14.00
$10.52
52W Range
$34.48
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
3.22
Current ratio
5.18
Debt / Equity
-0.32
ROE
-56.78%
Gross margin
-
Income growth
22.70%
FCF growth
-8.22
Analysts estimates
Consensus rating
Buy
The average rating from top 8 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$40.60
The top 13 analysts forecasts that 12-month price may increase by 196.32%, with a low of $26.26 and a high of $55.65
$26.26
Low
$40.60
Avg
$55.65
High
Current price
Earnings
Q1 ‘26 revenue
$0.00
Q1 ‘26 net income
-$35.72M
Revenue
Net income
Previous EPS
-$0.61
Estimate EPS
-$0.51
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply